Patents Assigned to EnClear Therapies, Inc.
  • Methods of treating neurological disorders
    Patent number: 11752200
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of toxic proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: September 12, 2023
    Assignee: EnClear Therapies Inc.
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Methods of treating neurological disorders
    Patent number: 11419921
    Abstract: Disclosed is a method for treating a subject having a neurological disorder characterized by the presence of dipeptide repeat proteins comprising contacting the cerebrospinal fluid (CSF) of the subject with an agent capable of removing or degrading the toxic protein.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: August 23, 2022
    Assignee: EnClear Therapies, Inc.
    Inventors: Manuel A. Navia, Kasper Roet, Jonathan Fleming
  • Methods of amelioration of cerebrospinal fluid and devices and systems therefor
    Patent number: 11278657
    Abstract: Cerebrospinal fluid (CSF) and other fluid amelioration systems completely or partially implantable within a mammalian subject and associated methods include a substrate and an agent for amelioration of a toxic biomolecule present in the CSF or fluid, wherein the agent is disposed on or within the substrate.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: March 22, 2022
    Assignee: EnClear Therapies, Inc.
    Inventors: Anthony DePasqua, Kevin Eggan, Jr., Kevin Kalish, Manuel A. Navia, Kasper Roet, Ching-Hua Tseng, Alan D. Watson, William X. Siopes, Gianna N. Riccardi, Marcie Ann Glicksman